[ad_1]
Everyone’s expectations are mounting …
The exact figures cannot be disclosed as an intermediate result …
Notably, interim results show that the COVID-19 vaccine jointly developed by Pfizer, a global pharmaceutical company in the United States, and Bioentech in Germany showed a prevention effect of more than 90% in clinical trials.
According to foreign media such as CNN and Reuters, on the 9th (local time), Pfizer analyzed 94 participants in the phase 3 clinical trial of the mRNA-based corona 19 vaccine ‘BNT162b2’, which is being developed, and revealed that it showed a prevention effect greater than 90%.
This result is based on initial data obtained from a global phase 3 clinical trial in a total of 43,538 participants from various races enrolled since July 27 in the United States and other countries around the world, and the Data Monitoring Committee ( Independent external DMC). It was an intermediate analysis.
Although the final figure may vary because it is an intermediate result, the prevention effect of more than 90% is almost twice as strong as that of a regular flu vaccine, so this result is highly anticipated. This phase 3 trial is scheduled to continue until a total of 164 confirmed cases are published.
Regarding the results, Pfizer CEO Albert Bulla said: “We have reached an important milestone when the world is struggling and needing the corona vaccine most.” “In the coming weeks, we have released additional data on the safety of the vaccine. I will do it.”
Ugur Sahin, CEO of Biotech also said: “This intermediate result provides evidence of the anti-corona effect of the vaccine.” “I am very grateful for the end of this journey.”
However, there have also been concerns among experts that it shouldn’t be too exciting as it is an intermediate result. In fact, when Pfizer announced the results of this phase 3 clinical trial, the detailed figures were not released, so it is not known exactly whether the vaccine has complications, the persistence of infection prevention and the effect on the elderly or seriously ill.
It is reported that Pfizer plans to apply to the Food and Drug Administration (FDA) for emergency use of the vaccine in the third week of November if no serious safety concerns are found after examining the vaccine’s safety data.
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited
